Low-Molecular-Weight Heparin as Bridging Anticoagulation During Interruption of Warfarin
Top Cited Papers
Open Access
- 28 June 2004
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 164 (12) , 1319-1326
- https://doi.org/10.1001/archinte.164.12.1319
Abstract
The treatment of patients with a mechanical heart valve or chronic atrial fibrillation who require temporary interruption of warfarin sodium therapy because of surgery or another invasive procedure is a frequently encountered but underinvestigated clinical problem.1-4 A major gap in knowledge is a lack of reliable estimates as to the incidence of thromboembolic events associated with warfarin therapy interruption.1 It is well established, however, that such events can have devastating clinical consequences: thrombosis of a mechanical heart valve is fatal in 15% of patients,5,6 and embolic stroke results in a major neurologic deficit or death in 70% of patients.7 Consequently, despite disagreement on the optimal periprocedural anticoagulation strategy during interruption of warfarin therapy,8-12 several authorities1-4 and consensus groups13,14 advocate, for most patients, some form of bridging therapy with a short-acting anticoagulant. The rationale for bridging anticoagulation is to minimize the time before and after a procedure that patients are not receiving therapeutic anticoagulation and, thereby, minimize the risk of thromboembolism. The conventional periprocedural anticoagulation approach is to hospitalize patients 4 to 5 days before surgery to stop warfarin and administer intravenous unfractionated heparin while the anticoagulant effect of warfarin recedes.15,16 Intravenous heparin is stopped 3 to 4 hours before the procedure to avoid a residual anticoagulant effect at the time of the procedure. After the procedure, warfarin and intravenous heparin are resumed, the latter administered for 4 to 5 days until therapeutic anticoagulation with warfarin is reestablished. This approach is difficult to implement because of the current constraints on hospital bed availability and the increasing number of surgical and other invasive procedures that are being performed without hospitalization.Keywords
This publication has 35 references indexed in Scilit:
- Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy: a practical guide for cliniciansThrombosis Research, 2002
- THE MANAGEMENT OF ANTICOAGULATION BEFORE AND AFTER PROCEDURESMedical Clinics of North America, 2001
- Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health StudyNeurology, 2001
- Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and SafetyChest, 2001
- Perioperative Management of the Chronically Anticoagulated PatientJournal of Thrombosis and Thrombolysis, 2001
- Management of Anticoagulation before and after Elective SurgeryNew England Journal of Medicine, 1997
- The management of anticoagulation in patients with prosthetic heart valves undergoing non-cardiac operationsPublished by Oxford University Press (OUP) ,1995
- Prosthetic heart valves and anticoagulant management during non-cardiac surgeryBritish Journal of Surgery, 1995
- The management of anticoagulation during noncardiac operations in patients with prosthetic heart valvesAmerican Heart Journal, 1978
- Discontinuing Anticoagulant Therapy in Surgical Patients With Cardiac Valve ProsthesesPublished by American Medical Association (AMA) ,1978